Naltrexonhydrochlorid Accord (Naltrexone Hydrochloride)

Naltrexone Hydrochloride is a competitive antagonist at mu, kappa, and delta opioid receptors. By occupying these receptors without activating them, it prevents endogenous opioids and opioid agonist drugs from binding, thereby diminishing the rewarding and reinforcing effects that contribute to substance use.

The specific dose of Naltrexonhydrochlorid Accord is determined by the prescribing clinician based on the individual’s medical condition, treatment goals, and response. Healthcare providers tailor the regimen to each patient, and the exact dosing schedule should be obtained from the prescriber’s instructions.

Safety data for naltrexone hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and discuss any concerns with the patient before prescribing during pregnancy or while breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with alternatives such as acamprosate for alcohol dependence or methadone/buprenorphine for opioid dependence, naltrexone offers a non‑opioid, antagonist approach that blocks receptor activation rather than providing substitution therapy. It is useful for patients seeking abstinence without opioid agonist exposure, though efficacy may vary based on adherence and support services.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency throughout its shelf life.

Naltrexonhydrochlorid Accord is taken orally, typically as a tablet swallowed with water. The exact administration schedule, including timing relative to meals, is determined by the prescribing clinician and should be followed as directed.

Serious risks include hepatotoxicity, severe depression or suicidal ideation, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of liver dysfunction, mood changes, or hypersensitivity, and seek immediate medical attention if any of these occur.

Contraindications include patients with acute opioid intoxication, those currently receiving opioid agonist therapy, and individuals with known hypersensitivity to naltrexone or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment.